Cadonilimab in China: match the diagnosis and treatment line

Cadonilimab is an infused antibody that targets two immune checkpoints, PD-1 and CTLA-4. It is not CAR-T or a general substitute for other immunotherapy.

China’s product information lists multiple indications with different partner medicines. A hospital should confirm the current label before judging a case.

The manufacturer’s published NMPA product information lists cadonilimab after platinum-based chemotherapy for relapsed or metastatic cervical cancer, and with platinum chemotherapy, with or without bevacizumab, for first-line persistent, recurrent or metastatic cervical cancer.

It also lists cadonilimab with fluoropyrimidine and platinum-based chemotherapy for first-line locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. These statements do not mean every patient with those diagnoses is eligible; pathology, prior therapy, health and regimen-specific criteria need review.

• Pathology report, stage and recent scan reports with images if available.
• Available PD-L1, HER2 and other biomarker results relevant to the diagnosis.
• Dated previous treatment and response, including platinum therapy for cervical cancer.
• Current medicines, autoimmune history, symptoms and a recent clinician summary.

Request a written specialist review of the diagnosis, treatment line and intended combination. Clarify tests, infusion schedule, monitoring and whether care can be arranged closer to home. An enquiry cannot guarantee a treatment slot.

A hospital reviews pathology and prior care, assesses whether cadonilimab is appropriate, selects any partner medicines, and sets infusion and monitoring visits. The plan may change with test results or adverse effects.

Ask separately about specialist assessment, pathology or biomarker review, cadonilimab, chemotherapy and bevacizumab if proposed, infusion visits, scans, adverse-event management and follow-up. Add travel and coordination costs only after the plan is clear.

Immune checkpoint treatment can cause immune-related effects in organs such as the lung, liver, bowel and endocrine glands. Combination chemotherapy or bevacizumab introduces further risks. The treating oncologist should explain warning symptoms and how complications will be managed.

A phase 3 gastric-cancer study informs population-level benefits and harms; it cannot predict an individual response or replace a review of contraindications.

For cervical or gastric cancer, choices depend on prior therapy, stage, biomarkers, performance status and local access. Ask the existing oncology team to compare other approved immunotherapy combinations, chemotherapy, targeted options, trials and supportive care.

We help present records and treatment-line questions clearly to a hospital team and coordinate practical steps. A licensed oncologist makes treatment decisions; MedRelay does not promise access or outcomes.